WO2003086267B1 - Multi-phase, multi-compartment capsular system - Google Patents

Multi-phase, multi-compartment capsular system

Info

Publication number
WO2003086267B1
WO2003086267B1 PCT/US2003/010816 US0310816W WO03086267B1 WO 2003086267 B1 WO2003086267 B1 WO 2003086267B1 US 0310816 W US0310816 W US 0310816W WO 03086267 B1 WO03086267 B1 WO 03086267B1
Authority
WO
WIPO (PCT)
Prior art keywords
capsule
receiving chamber
compartment
chamber
primary
Prior art date
Application number
PCT/US2003/010816
Other languages
French (fr)
Other versions
WO2003086267A2 (en
WO2003086267A3 (en
Inventor
Fred H Miller
Lance R Ausec
Original Assignee
Fred H Miller
Lance R Ausec
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US10/369,244 external-priority patent/US20030194429A1/en
Priority to CA2481486A priority Critical patent/CA2481486C/en
Priority to EP03717010A priority patent/EP1499303A4/en
Priority to JP2003583294A priority patent/JP2005528383A/en
Priority to NZ536267A priority patent/NZ536267A/en
Priority to AU2003220689A priority patent/AU2003220689A1/en
Application filed by Fred H Miller, Lance R Ausec filed Critical Fred H Miller
Publication of WO2003086267A2 publication Critical patent/WO2003086267A2/en
Publication of WO2003086267A3 publication Critical patent/WO2003086267A3/en
Priority to US10/804,576 priority patent/US7670612B2/en
Publication of WO2003086267B1 publication Critical patent/WO2003086267B1/en
Priority to US12/689,669 priority patent/US8361497B2/en
Priority to US13/746,743 priority patent/US20130136791A1/en
Priority to US14/036,521 priority patent/US9241911B2/en
Priority to US15/005,508 priority patent/US9539216B2/en

Links

Classifications

    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B29—WORKING OF PLASTICS; WORKING OF SUBSTANCES IN A PLASTIC STATE IN GENERAL
    • B29C—SHAPING OR JOINING OF PLASTICS; SHAPING OF MATERIAL IN A PLASTIC STATE, NOT OTHERWISE PROVIDED FOR; AFTER-TREATMENT OF THE SHAPED PRODUCTS, e.g. REPAIRING
    • B29C39/00—Shaping by casting, i.e. introducing the moulding material into a mould or between confining surfaces without significant moulding pressure; Apparatus therefor
    • B29C39/02—Shaping by casting, i.e. introducing the moulding material into a mould or between confining surfaces without significant moulding pressure; Apparatus therefor for making articles of definite length, i.e. discrete articles
    • B29C39/10—Shaping by casting, i.e. introducing the moulding material into a mould or between confining surfaces without significant moulding pressure; Apparatus therefor for making articles of definite length, i.e. discrete articles incorporating preformed parts or layers, e.g. casting around inserts or for coating articles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61J—CONTAINERS SPECIALLY ADAPTED FOR MEDICAL OR PHARMACEUTICAL PURPOSES; DEVICES OR METHODS SPECIALLY ADAPTED FOR BRINGING PHARMACEUTICAL PRODUCTS INTO PARTICULAR PHYSICAL OR ADMINISTERING FORMS; DEVICES FOR ADMINISTERING FOOD OR MEDICINES ORALLY; BABY COMFORTERS; DEVICES FOR RECEIVING SPITTLE
    • A61J3/00—Devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms
    • A61J3/07—Devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms into the form of capsules or similar small containers for oral use
    • A61J3/071—Devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms into the form of capsules or similar small containers for oral use into the form of telescopically engaged two-piece capsules
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4808—Preparations in capsules, e.g. of gelatin, of chocolate characterised by the form of the capsule or the structure of the filling; Capsules containing small tablets; Capsules with outer layer for immediate drug release
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4833—Encapsulating processes; Filling of capsules
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4858—Organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4866—Organic macromolecular compounds
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B29—WORKING OF PLASTICS; WORKING OF SUBSTANCES IN A PLASTIC STATE IN GENERAL
    • B29K—INDEXING SCHEME ASSOCIATED WITH SUBCLASSES B29B, B29C OR B29D, RELATING TO MOULDING MATERIALS OR TO MATERIALS FOR MOULDS, REINFORCEMENTS, FILLERS OR PREFORMED PARTS, e.g. INSERTS
    • B29K2105/00—Condition, form or state of moulded material or of the material to be shaped
    • B29K2105/0058—Liquid or visquous
    • B29K2105/0061—Gel or sol

Abstract

A multi-compartment capsule, comprising, a first receiving chamber comprising at least one ingredient having a first physical state, wherein said ingredient is selected from the group consisting of a nutraceutical, a vitamin, a dietary supplement and a mineral; and a second receiving chamber comprising at least one ingredient having a second physical state, wherein said ingredient is selected from the group consisting of a nutraceutical, a vitamin, a dietary supplement and a mineral; wherein said first physical state of said ingredient of said first receiving chamber being different from said second physical state of said ingredient of said second receiving chamber; and said ingredient of said first receiving chamber being different from said ingredient of said second receiving chamber.

Claims

AMENDED CLAIMS
[Received by the International Bureau on 17 December 2003 (17.12.03); new claims 119-144 added (3 pages)]
11 _. A multi-compartment capsule according to claim 50, wherein the first capsule contains Fluoxetine, the second capsule contains S-adenosylmethione, and the third receiving capsule contains Vitamin E.
119. A multi-compartment capsule as defined in claim 1, wherein the first receiving chamber surrounds the second receiving chamber.
120. A multi-compartment capsule as defined in claim 1, wherein the first receiving chamber and the second receiving chamber have hard chamber walls.
121. A multi-compartment capsule as defined in claim 120, wherein the first receiving chamber and the second receiving chamber further comprise: a base and a corresponding cap, wherein said cap is sealingly engaged with said base to form the respective chamber.
122. A multi-compartment capsule as defined in claim 1, wherein at least one of the first receiving chamber and the second receiving chamber have a soft chamber wall.
123. A multi-compartment capsule as defined in claim 1, wherein the material of least one of the first receiving chamber and the second receiving chamber consists essentially of hydroxyprophl methyl cellulose and about 0% plasticizer.
124. A multi-compartment capsule as defined in claim 10, wherein the primary capsule surrounds the secondary capsule.
125. A multi-compartment capsule as defined in claim 10, wherein the primary capsule and the secondary capsule have hard capsule walls.
126. A multi-compartment capsule as defined in claim 125, wherein the primary capsule and the secondary capsule further comprise: a base and a corresponding cap, wherein said cap is sealingly engaged with said base to form the respective capsule.
127. A multi-compartment capsule as defined in claim 10, wherein at least one of the primary capsule and the secondary capsule have a soft capsule wall.
128. A multi-compartment capsule as defined in claim 10, wherein the material of least one of the primary capsule and the secondary capsule chamber consists essentially of hydroxyprophl methyl cellulose and about 0% plasticizer.
129. The process of claim 16, wherein the primary capsule and the secondary capsule have hard capsule walls.
130. The process of claim 16, wherein at least one of the primary capsule and the secondary capsule have a soft capsule wall.
131. The process of claim 16, wherein the material of least one of the primary capsule and the secondary capsule chamber consists essentially of hydroxyprophl methyl cellulose and about 0% plasticizer.
132. A multi-compartment capsule as defined in claim 36, wherein the first receiving chamber surrounds the second receiving chamber.
133. A multi-compartment capsule as defined in claim 36, wherein the first receiving chamber and the second receiving chamber have hard chamber walls.
134. A multi-compartment capsule as defined in claim 133, wherein the first receiving chamber and the second receiving chamber further comprise: a base and a corresponding cap, wherein said cap is sealingly engaged with said base to form the respective capsule.
135. A multi-compartment capsule as defined in claim 36, wherein at least one of the first receiving chamber and the second receiving chamber have a soft chamber wall.
136. A multi-compartment capsule as defined in claim 36, wherein the material of least one of the first receiving chamber and the second receiving chamber consists essentially of hydroxyprophl methyl cellulose and about 0% plasticizer.
137. The process of claim 60, wherein the primary capsule and the secondary capsule have hard capsule walls.
138. The process of claim 60, wherein at least one of the primary capsule and the secondary capsule have a soft capsule wall.
139. The process of claim 60, wherein the material of least one of the primary capsule and the secondary capsule chamber consists essentially of hydroxyprophl methyl cellulose and about 0% plasticizer.
140. A multi-compartment capsule as defined in claim 36, wherein the first receiving chamber surrounds the second receiving chamber, and wherein the ingredients include pharmaceuticals.
141. A multi-compartment capsule as defined in claim 36, wherein the first receiving chamber and the second receiving chamber have hard chamber walls, and wherein the ingredients include pharmaceuticals.
142. A multi-compartment capsule as defined in claim 136, wherein the ingredients include pharmaceuticals.
143. The process of claim 60, wherein the primary capsule and the secondary capsule have hard capsule walls, and wherein the ingredients include pharmaceuticals.
144. The process of claim 60, wherein at least one of the primary capsule and the secondary capsule have a soft capsule wall, and wherein the ingredients include pharmaceuticals. ,
PCT/US2003/010816 2002-04-10 2003-04-09 Multi-phase, multi-compartment capsular system WO2003086267A2 (en)

Priority Applications (10)

Application Number Priority Date Filing Date Title
CA2481486A CA2481486C (en) 2002-04-10 2003-04-09 Multi-phase, multi-compartment capsular system
EP03717010A EP1499303A4 (en) 2002-04-10 2003-04-09 Multi-phase, multi-compartment capsular system
JP2003583294A JP2005528383A (en) 2002-04-10 2003-04-09 Multiphase, multiple compartment capsule system
NZ536267A NZ536267A (en) 2002-04-10 2003-04-09 Multi-phase, multi-compartment and multi-ingredient capsular system
AU2003220689A AU2003220689A1 (en) 2002-04-10 2003-04-09 Multi-phase, multi-compartment capsular system
US10/804,576 US7670612B2 (en) 2002-04-10 2004-03-19 Multi-phase, multi-compartment capsular delivery apparatus and methods for using same
US12/689,669 US8361497B2 (en) 2002-04-10 2010-01-19 Multi-phase, multi-compartment, capsular delivery apparatus and methods for using the same
US13/746,743 US20130136791A1 (en) 2002-04-10 2013-01-22 Multi-phase, mult-compartment capsular delivery apparatus and methods for using same
US14/036,521 US9241911B2 (en) 2002-04-10 2013-09-25 Multi-phase, multi-compartment, capsular delivery apparatus and methods for using same
US15/005,508 US9539216B2 (en) 2002-04-10 2016-01-25 Multi-phase, multi-compartment, capsular delivery apparatus and methods for using same

Applications Claiming Priority (10)

Application Number Priority Date Filing Date Title
US37144802P 2002-04-10 2002-04-10
US60/371,448 2002-04-10
US10/369,247 2003-02-18
US10/369,244 US20030194429A1 (en) 2002-04-10 2003-02-18 Multi-phase, multi-compartment capsular delivery apparatus for therapeutic compositions and methods for using same
US10/369,247 US20030194430A1 (en) 2002-04-10 2003-02-18 Process for encapsulating multi-phase, multi-compartment capsules for therapeutic compositions
US10/369,244 2003-02-18
US10/368,951 2003-02-18
US10/368,951 US20030194428A1 (en) 2002-04-10 2003-02-18 Process for encapsulating multi-phase, multi-compartment capsules
US10/369,427 2003-02-18
US10/369,427 US20030194431A1 (en) 2002-04-10 2003-02-18 Multi-phase,multi-compartment capsular delivery apparatus and methods for using same

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
US37144802P Substitution 2002-04-10 2002-04-10

Related Child Applications (1)

Application Number Title Priority Date Filing Date
US10/804,576 Continuation-In-Part US7670612B2 (en) 2002-04-10 2004-03-19 Multi-phase, multi-compartment capsular delivery apparatus and methods for using same

Publications (3)

Publication Number Publication Date
WO2003086267A2 WO2003086267A2 (en) 2003-10-23
WO2003086267A3 WO2003086267A3 (en) 2003-12-18
WO2003086267B1 true WO2003086267B1 (en) 2004-04-29

Family

ID=29255682

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2003/010816 WO2003086267A2 (en) 2002-04-10 2003-04-09 Multi-phase, multi-compartment capsular system

Country Status (6)

Country Link
EP (1) EP1499303A4 (en)
JP (2) JP2005528383A (en)
AU (3) AU2003220689A1 (en)
CA (1) CA2481486C (en)
NZ (1) NZ536267A (en)
WO (1) WO2003086267A2 (en)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8383579B2 (en) 2004-11-19 2013-02-26 GlaxoSmithKline, LLC Method for customized dispensing of variable dose drug combination products for individualizing of therapies

Families Citing this family (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CZ2002336A3 (en) 1999-07-30 2002-06-12 Smithkline Beecham Plc Multicomponent pharmaceutical dosage form
US20040087527A1 (en) 2002-10-31 2004-05-06 Day Brian J. Methods for treatment of thiol-containing compound deficient conditions
US7790762B2 (en) 2002-10-31 2010-09-07 National Jewish Health Compounds and methods for thiol-containing compound efflux and cancer treatment
DE10359792A1 (en) * 2003-12-19 2005-07-21 Bayer Technology Services Gmbh Multiphasic drug formulation
JP4963670B2 (en) * 2004-04-07 2012-06-27 レスベラトロル パートナーズ， エルエルシー Nutritional supplements and methods for processing them
US7981908B2 (en) * 2005-05-11 2011-07-19 Vecta, Ltd. Compositions and methods for inhibiting gastric acid secretion
US7803817B2 (en) 2005-05-11 2010-09-28 Vecta, Ltd. Composition and methods for inhibiting gastric acid secretion
JP2006321730A (en) * 2005-05-17 2006-11-30 Maruzen Pharmaceut Co Ltd Antioxidant, antiaging agent, skin cosmetics, and food or drink
US7781572B2 (en) * 2005-10-05 2010-08-24 Nse Products, Inc. Nanosized carotenoid cyclodextrin complexes
EP3332788A1 (en) 2006-02-03 2018-06-13 Opko Renal, LLC Treating vitamin d insufficiency and deficiency with 25-hydroxyvitamin d2 and 25-hydroxyvitamin d3
ES2670029T3 (en) 2006-06-21 2018-05-29 Opko Ireland Global Holdings, Ltd. Therapy using vitamin D replenishment agent and vitamin D hormone replacement agent
DK2046334T3 (en) 2006-07-25 2014-08-25 Vecta Ltd Compositions and Methods to Inhibit Stomach Acid Secretion Using Derivatives of Small Dicarboxylic Acids in Combination with PPI
US20130115320A1 (en) 2007-03-30 2013-05-09 Dynova Laboratories, Inc. Therapeutic agent for intranasal administration and method of making and using same
KR101691876B1 (en) 2007-04-25 2017-01-02 사이토크로마 인코포레이티드 Oral controlled release compositions comprising vitamin d compound and waxy carrier
US11752158B2 (en) 2007-04-25 2023-09-12 Eirgen Pharma Ltd. Method of treating vitamin D insufficiency and deficiency
US7867524B2 (en) 2007-10-05 2011-01-11 David Rowland Energizing formulation
US20120145572A1 (en) * 2009-04-20 2012-06-14 Ecole Polytechnique Federale De Lausanne (Epfl) Containers assembled in fluid and corresponding production
KR101143997B1 (en) * 2010-03-04 2012-05-09 한미사이언스 주식회사 Complex formulation for oral administration comprising probiotic formulation and 5-ht4 receptor agonist and method for the preparation thereof
HUE048464T2 (en) 2010-03-29 2020-07-28 Opko Ireland Global Holdings Ltd Methods and compositions for reducing parathyroid levels
CA3065589C (en) 2010-06-03 2022-04-26 Catalent Ontario Limited Multi phase soft gel capsules, apparatus and method thereof
WO2012017326A2 (en) * 2010-07-19 2012-02-09 Procaps Sa Apparatus and process for encapsulating capsules or other solid dosage forms within capsules
US20120082719A1 (en) * 2010-10-05 2012-04-05 Sam Poon Ang Compositions For Treating Chronic Viral Infections
CN102335095A (en) * 2011-10-12 2012-02-01 李思思 Manufacturing technology of d-limonene hard capsules
CA2906945A1 (en) 2013-03-15 2014-09-18 Incube Labs, Llc Multi-stage biodegradable drug delivery platform
KR101847947B1 (en) 2013-03-15 2018-05-28 옵코 아이피 홀딩스 Ⅱ 인코포레이티드 Stabilized modified release vitamin d formulation
SG10201911274TA (en) * 2014-08-07 2020-02-27 Opko Ireland Global Holdings Ltd Adjunctive therapy with 25-hydroxyvitamin d
US9980993B2 (en) 2014-11-06 2018-05-29 NWO Stem Cure, LLC Nutraceutical supplement with Lactobacillus rhamnosus
US9468659B2 (en) 2014-11-06 2016-10-18 NWO Stem Cure, LLC Nutraceutical supplement with Lactobacillus rhamnosus
TWI747893B (en) 2016-03-28 2021-12-01 愛爾蘭商歐科愛爾蘭全球控股股份有限公司 Methods of vitamin d treatment
CN108753621A (en) * 2018-05-30 2018-11-06 昆明理工大学 A method of based on molasses give up mash improve single needle algae oil and fat accumulation
JP7229012B2 (en) * 2018-12-25 2023-02-27 小林製薬株式会社 Pharmaceutical composition for internal use
IT201900025063A1 (en) * 2019-12-20 2021-06-20 Idi Integratori Dietetici Italiani S R L GASTRORESISTANT COMPOSITIONS INCLUDING INOSITOL AND / OR SYLVESTRE GYMNEMA EXTRACT, THEIR PHARMACEUTICAL AND NUTRACEUTICAL COMPOSITIONS AND THEIR USE
CN116648239A (en) * 2021-08-26 2023-08-25 宁德时代新能源科技股份有限公司 Liquid bag, battery monomer, battery and electricity utilization device

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2729068A1 (en) * 1977-06-28 1979-01-11 Rainer Dr Med Liedtke Releasing incompatible pharmaceuticals from capsules - by including a second capsule inside the first
US4185740A (en) * 1978-08-02 1980-01-29 Johnson & Johnson Disposable capsules
CH661878A5 (en) * 1983-11-04 1987-08-31 Warner Lambert Co CAPSULE DOSING FORMS.
JPS6342094Y2 (en) * 1985-07-02 1988-11-04
DE3543154A1 (en) * 1985-12-06 1987-06-11 Boehringer Ingelheim Kg DIVISIBLE CAPSULE
US4940499A (en) * 1989-05-23 1990-07-10 Warner-Lambert Company Method and apparatus for sealing capsules containing medicaments
DE69013923T2 (en) * 1989-08-17 1995-03-16 Cortecs Ltd MEDICINAL FORMULATIONS.
US5501857A (en) * 1992-07-24 1996-03-26 Midwestern Bio-Ag Products & Services, Inc. Oral nutritional and dietary composition
JPH06316517A (en) * 1993-02-22 1994-11-15 Grelan Pharmaceut Co Ltd Sustained-release preparation
JP2000239159A (en) * 1999-02-19 2000-09-05 Nitto Yakuhin Kogyo Kk Capsule preparation and it production
AR031068A1 (en) * 1999-04-13 2003-09-10 Beecham Pharm Pte Ltd A PHARMACEUTICAL FORMULATION OF MODIFIED RELEASE THAT INCLUDES AMOXICILLIN AND POTASSIUM CLAVULANATE IN A RATIO OF 2: 1 TO 20: 1, A COMPRESSED IN LAYERS, THE USE OF AMOXYCLINE AND THE POTASSIUM CLAVULANATE FOR THE MANUFACTURE OF A MEDICINAL PRODUCT COMPACT GRANULES
EP1457431A3 (en) * 1999-11-17 2007-07-04 Aquasol Limited Injection moulded water-soluble container
US6372252B1 (en) * 2000-04-28 2002-04-16 Adams Laboratories, Inc. Guaifenesin sustained release formulation and tablets
US7445795B2 (en) * 2000-07-20 2008-11-04 Mw Encap Limited Delivery device, method of using and method of manufacturing

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8383579B2 (en) 2004-11-19 2013-02-26 GlaxoSmithKline, LLC Method for customized dispensing of variable dose drug combination products for individualizing of therapies

Also Published As

Publication number Publication date
CA2481486C (en) 2012-06-12
AU2009202495B2 (en) 2011-02-10
NZ536267A (en) 2007-06-29
JP2005528383A (en) 2005-09-22
WO2003086267A2 (en) 2003-10-23
AU2003220689A1 (en) 2003-10-27
WO2003086267A3 (en) 2003-12-18
EP1499303A2 (en) 2005-01-26
JP2011068664A (en) 2011-04-07
AU2009202495A1 (en) 2009-07-16
CA2481486A1 (en) 2003-10-23
EP1499303A4 (en) 2007-07-25
AU2011202164A1 (en) 2011-06-02

Similar Documents

Publication Publication Date Title
WO2003086267B1 (en) Multi-phase, multi-compartment capsular system
CA2159580A1 (en) Pharmaceutical Compositions Containing Polyvinylpyrrolidone and a Tri-Ester and Process of Manufacture Thereof
CA2327723A1 (en) Bicyclic hydroxamic acid derivatives
AU3080895A (en) Novel piperazides derived from arylpiperazine, processes for their preparation, their use as medicaments and pharmaceutical compositions comprising them
HUP0201711A2 (en) Indanyl-substituted benzole carbonamide, method for the production of the same, use thereof as a medicament and pharmaceutical preparations containing the same
CA2326485A1 (en) Anticancer compositions
NO20020055L (en) Mixture suitable to form a soft capsule, as well as edible soft capsule.
IL148288A0 (en) Indolealkanol ester and indolealkylamide derivatives, processes for the preparation thereof and pharmaceutical compositions containing the same
CA2419314A1 (en) Preparation of risperidone
CA2175529A1 (en) Synergistic stabilizer mixture
CA2450093A1 (en) Stable polymorph of flibanserin, technical process for its preparation and the use thereof for preparing medicaments
DE69502147T2 (en) L-carnitine salt and compositions containing it
CA2348953A1 (en) Cushioning wax beads for making solid shaped articles
DE3574933D1 (en) SOLID PHARMACEUTICAL PREPARATION CONTAINING NITRENDIPINE AND METHOD FOR THE PRODUCTION THEREOF.
GEP20063972B (en) Streptogramin derivatives, preparation and compositions containing them
AU2841199A (en) Novel bis-benzamide derivatives, method for making same pharmaceutical compositions containing them and use thereof as medicine
WO2002008222A3 (en) HETEROARYL-β-ALANINE DERIVATIVES AS ALPHA 4 INTEGRIN INHIBITORS
CA2174707A1 (en) Chromone derivatives as nk1 and substance p antagonists
HUP0303195A3 (en) O-substituted 6-methyl-tramadol derivatives, process for their preparation and pharmaceutical compositions containing them
ZA200100565B (en) Benzenesulfonamide compounds, a process for their preparation and pharmaceutical compositions containing them.
HU9800374D0 (en) Sulfonamide-substituted chromanes, process for producing them, their use as medicines or diagnostics, and pharmaceutical compositions containing them
ZA968762B (en) Derivatives of acid pyrazoles, their preparation process, their use as medicaments, their new use and the pharmaceutical compositions containing them.
HUP9802518A3 (en) Sulfonamide-substituted benzopirane derivatives, process for producing them, their use as pharmaceuticals and pharmaceutical compositions containing them
AU2001291695A1 (en) Method for the production of capsules containing active ingredients by miniemulsion polymerisation
HUP9800395A3 (en) Sulfonamide-substituted benzoxepine derivatives, their use as medicines and pharmaceutical compositions containing them

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NI NO NZ OM PH PL PT RO RU SC SD SE SG SK SL TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 10804576

Country of ref document: US

B Later publication of amended claims

Effective date: 20031217

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
WWE Wipo information: entry into national phase

Ref document number: 2481486

Country of ref document: CA

Ref document number: 2003583294

Country of ref document: JP

WWE Wipo information: entry into national phase

Ref document number: 2003220689

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 536267

Country of ref document: NZ

WWE Wipo information: entry into national phase

Ref document number: 2003717010

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 2003717010

Country of ref document: EP